PTC Therapeutics officer proposes $178K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
PTC Therapeutics, Inc. (PTCT) officer Mark Elliott Boulding gave notice of a proposed sale of 2,812 common shares, with an aggregate market value of $177,887.12 and an approximate sale date of November 16, 2026. The notice lists the shares as acquired from the issuer through a stock option exercise for cash on November 16, 2026. It gives September 10, 2025 as the date of plan adoption or instruction, if relying on Rule 10b5-1.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Stock Option Exercise financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Rule 10b5-1 plan date is associated with Mark Elliott Boulding's PTCT sale?
What earlier PTCT sales did Mark Elliott Boulding report?
AI-generated analysis. How Rhea-AI works. Not financial advice.